,,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['trastuzumab', 'mbc', 'bcsm', 'breast', 'enhertu']
game changer in her2 low mbc. i will be putting patients on this come tuesday. enhertu reduces risk of progression by 49% and risk of death by 34%. #bcsm #asco22 trastuzumab deruxtecan in previously treated her2-low advanced breast cancer | nejm 
Breast & gyn med onc @valleyhospital in NJ. Focus on survivorship and ?????? onc. All opinions my own. Retweets not endorsements. Host of INTERLUDE podcast ??